| XENOG ENEI C CELL TR ANS PL ANTATION UNDER THE " REG ENER ATIVE MED I CINE PROMOTI ON AC T "
In Japan, the "Regenerative Medicine Promotion Act" was approved and promulgated in 2013, and came into effect in the same year.
The objective of this Act is to promote the comprehensive policies regarding regenerative medicine, from research and development to clinical implementation. Furthermore, the "Act on the Safety of Regenerative Medicine" and the "Revised Pharmaceutical Affairs Act" were approved and promulgated in 2013, and came into effect in 2014 (https://www.mhlw.go.jp/english/policy/health-medical/ medical-care/dl/150407-01.pdf).
| Act on the safety of regenerative medicine
The "Act on the Safety of Regenerative Medicine" includes new standards for institutions providing regenerative medicine and cell culturing and processing facilities. These standards are intended to ensure the safety of regenerative medicine. Additionally, this Act enables medical institutions to outsource cell culturing and processing to companies for swift implementation. To ensure safety, this Act stipulates three risk-dependent provision standards and procedures for the notification of plans for regenerative medicine as well as standards for cell culturing and processing facilities, licensing procedures, etc.
There are three classes of risk-dependent procedures, namely, high risk (Class I), medium risk (Class II), and low risk (Class III). Class To provide Class I regenerative medicine, a medical institution must submit an application to a certified special committee for regenerative medicine. This committee is authorized and capable of conducting thorough and objective investigations. The committee reviews the application, after which a plan is submitted to the Ministry of Health, Labour and Welfare (MHLW). If indicated, the MHLW can order changes to the plan based on the opinions of health science council members.
| Revised pharmaceutical affairs act
A new entity ("regenerative medicine products") was included in the "Revised Pharmaceutical Affairs Act" for marketing purposes. The demonstration of efficacy in an exploratory study is sufficient for a provisional approval that will grant the product a conditional term of 7 years, during which additional data regarding efficacy and safety should be collected while the product is marketed. Regarding safety, this Act adopts post-marketing safety measures, including the need to obtain informed consent from patients for the use of the product, recordings, and stored information.
| UPDATED " PUB LI C HE ALTH G U IDELINE S ON INFEC TI OUS D IS E A S E ISSUE S IN XENOTR ANS PL ANTATION "
In go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000133010.pdf), and the main topics are listed in Table 1 .
| OPINI ON S ABOUT IS LE T XENOTR ANS PL ANTATION
The goal of islet xenotransplantation is to improve the quality of life (QOL) of patients. Because QOL is assessed by the patients themselves, 3 understanding the patients' opinions regarding islet xenotransplantation is important. We conducted surveys involving Japanese patients with type 1 diabetes and their family members.
The survey was conducted three times, and participants were asked questions related to islet xenotransplantation (Table 2 ).
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The first allogeneic islet transplantation in Japan was performed in 2004. 7 their family members, 6 with family members having a more positive opinion than the patients. Nevertheless, many Japanese patients and their families indicated they would accept islet xenotransplantation, implying this treatment has become socially acceptable in Japan.
| JAPAN AG EN C Y FOR MED IC AL RE S E ARCH AND DE VELOPMENT ( AMED) SUPP ORT
A clinical xenotransplantation has not been conducted in Japan.
However, a research grant was submitted to AMED by the National Institute for Global Health and Medicine to promote islet xenotransplantation. The grant was approved in 2018, and research toward a clinical trial has been initiated. This grant approval by AMED indicates that the Japanese government supports islet xenotransplantation.
| CELL-PRO CE SS ING CENTER FOR IS LE T XENOTR ANS PL ANTATION
For clinical islet xenotransplantation, an approved cell-processing center (CPC) is required under the "Act on the Safety of Regenerative
Medicine." A CPC dedicated to islet xenotransplantation is being constructed at the National Institute for Global Health and Medicine with the support of an organization for type 1 diabetes patients (Japan IDDM network). This center will be the first of its kind in Japan.
| DE VELOPMENT OF G ERM -FREE PI G S IN JAPAN
The updated "Public Health Guidelines on Infectious Disease Issues in Xenotransplantation" indicates that designated pathogen-free derivation system involving hysterectomy of wild-type pigs to optimize the piglet delivery conditions. 8 In this system, they excised the uterus with the fetus from the anesthetized mother pig just before birth and transferred it to a plastic isolator through a tank for decontamination. The piglet was then removed from the uterus in the isolator and transferred to a rearing isolator. The overall resuscitation rate was 21/32 (66%) and the germ-free rate was 17/20 (85%).
This system for producing germ-free pigs can be used for generating clinical-grade xenografts or human tissues from pluripotent pig stem cells (eg, pancreatic islets). 9 The updated "Public Health Guidelines on Infectious Disease
Issues in Xenotransplantation" lists the banned pathogens. However, several of these pathogens are rarely detected in Japan. Therefore, for clinical applications, Japanese DPF pigs should be defined as pigs in which pathogens are eliminated which exists in Japan based on scientific evidence. 
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